Phase 1-2 study | Adagrasib with or without Cetuximab in colorectal cancer with mutated KRAS G12C
9 Jan, 2023 | 14:04h | UTCAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Advanced Colorectal Cancer Treatment Targets KRAS Gene With Drug Combo – Memorial Sloan Kettering Cancer Center
Commentary on Twitter
In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor receptor antibody. https://t.co/nCoEPeV9oB pic.twitter.com/FCHxU9WCin
— NEJM (@NEJM) December 21, 2022